Orris

Tumour Infiltrating lymphocytes

Reading Document
Tumor-infiltrating lymphocytes (TILs) are immune cells, mainly T cells, that have migrated from blood into the tumor microenvironment.

Why they matter

  • Marker of anti-tumor immunity: More TILs often means the immune system is recognizing the cancer.
  • Prognostic value: In several cancers (especially melanoma, triple-negative breast cancer, some colorectal and ovarian cancers), higher TIL levels are often linked to better outcomes.
  • Predictive value for therapy: TIL-rich (“inflamed”) tumors are more likely to respond to immune checkpoint inhibitors in some settings.

Types

  • CD8+ cytotoxic T cells: directly kill tumor cells
  • CD4+ helper T cells: coordinate immune responses
  • Regulatory T cells (Tregs): can suppress anti-tumor immunity
  • B cells, NK cells, macrophages may also be present in the infiltrate

Clinical use

  1. Pathology reporting: TIL density can be assessed on biopsy/resection slides.
  2. Biomarker role: helps risk stratification and treatment planning in selected cancers.
  3. Cell therapy (TIL therapy):
    • Tumor sample is removed
    • TILs are expanded in the lab
    • Given back to patient after lymphodepleting chemo
    • Often combined with IL-2 support
      This is an approved/advanced approach in some melanoma settings and under study in others.
If you want, I can also give you:
  • a cancer-specific summary (for breast, melanoma, lung, etc.),
  • how TILs are scored on histology,
  • or a simple diagram-style explanation.

Cancer and immune system and lymphopenia

Good link between these topics. Here is the short framework:

1) Cancer and the immune system

The immune system can both fight and shape cancer.
  • Elimination: immune cells detect and kill abnormal cells
  • Equilibrium: some tumor cells survive under immune pressure
  • Escape: tumor evolves mechanisms to avoid immune attack
Common tumor immune-escape mechanisms:
  • Reduced antigen presentation (less visible to T cells)
  • PD-L1 expression and other checkpoint pathways
  • Immunosuppressive microenvironment (Tregs, MDSCs, suppressive cytokines)
  • Physical exclusion of T cells from tumor tissue

2) Lymphopenia in cancer

Lymphopenia = low lymphocyte count (usually low absolute lymphocyte count on CBC).
In cancer patients, causes are often multifactorial:
  • Cancer itself (marrow involvement, chronic inflammation, nutritional decline)
  • Treatment-related:
    • Chemotherapy
    • Radiotherapy (especially large fields)
    • Corticosteroids
    • Some targeted/immunosuppressive agents
  • Infections or sepsis
  • Advanced disease/cancer cachexia

3) Why lymphopenia matters

  • Higher infection risk
  • Reduced anti-tumor immune surveillance
  • Often associated with poorer prognosis in several cancers
  • May reduce response to some immunotherapies (context-dependent)

4) Practical clinical approach

  1. Confirm severity and trend of lymphocyte count (repeat CBC)
  2. Review recent cancer therapies and steroid exposure
  3. Screen for reversible causes (infection, nutrition, medications)
  4. Assess symptoms/signs of opportunistic infection
  5. Risk-stratify and consider prophylaxis when indicated
  6. Coordinate oncology plan adjustments if persistent severe lymphopenia

5) Relationship to TILs (from your prior question)

  • You can have systemic lymphopenia (low blood lymphocytes) and still have variable local tumor infiltration.
  • In general, a more functional T-cell compartment supports better anti-tumor response.
  • Cancer biology is local + systemic:
    TILs = local tumor immune activity,
    lymphocyte count = systemic immune reserve.
If you want, I can make a quick table with:
  • mild/moderate/severe lymphopenia cutoffs,
  • common oncology causes,
  • and when to suspect urgent infection risk.
This is a shared conversation. Sign in to Orris to start your own chat.